Shire Tightens R&D Focus, And Decision-Making Criteria
This article was originally published in The Pink Sheet Daily
Executive Summary
Having winnowed its pipeline and established a tighter focus on rare diseases, Shire will assess each early-stage candidate on the basis of stringent “go/no-go” criteria to rein in R&D spending, Global R&D Chief Phil Vickers said.